Andrea Gentile, Michele Introna, Michel M. R. F. Struys, Johannes P. van den Berg
<p>Target-controlled infusions have been criticised as too slow for a rapid sequence induction (RSI), due primarily to the maximum infusion rate of commercially available pumps (approximately 1200 ml.h<sup>-1</sup>). Despite the widespread adoption of total intravenous anaesthesia, there is limited consensus on what truly defines a ‘rapid’ induction of general anaesthesia, and no standardised description of RSI components exists [<span>1</span>]. A new feature in commercial target-controlled infusion pumps enables administration of an additional manual bolus to accelerate induction of anaesthesia [<span>2</span>]. The rationale relies on comparing a 5 s manual bolus with a capped 1200 ml.h<sup>-1</sup> infusion rate, supported by proof-of-concept simulation in a single virtual subject. This study extends that concept by providing a simulation-based pharmacokinetic proof of feasibility for target-controlled infusions use in RSI.</p><p>Simulations were performed using the Python Anaesthesia Simulator [<span>3</span>], which incorporates the Eleveld population model for propofol. Virtual patients were defined as 35-year-old males, 175 cm in height, with bodyweights ranging from 40 kg to 160 kg and assuming concomitant opioid administration. To isolate the effect of bodyweight on model performance and infusion limitations, we kept age, sex, height and opioid co-administration fixed across simulations, varying weight only. This approach ensured that differences in onset dynamics were attributable to weight-dependent changes in pharmacokinetics and to the infusion-rate cap of the pump, rather than to covariate interactions. Using propofol 1%, three induction doses were evaluated (1.5, 2.0 and 2.5 mg.kg<sup>-1</sup>), administered by two modalities: target-controlled infusion at a high infusion rate of 1200 ml.h<sup>-1</sup>; and a manual bolus delivered at 3360 ml.h<sup>-1</sup>. Without standardised guidelines for propofol administration during RSI, a manual bolus of 2 mg.kg<sup>-1</sup> over 15 s in a 70 kg patient was assumed. Simulation infusions continued until the full dose was delivered.</p><p>Time to peak effect-site concentration was used as a marker of induction speed, while peak plasma concentration of propofol served as a surrogate for risk of overshoot and haemodynamic instability. Although these indices do not capture loss of consciousness directly or clinical responses, they provide mechanistically relevant markers of onset dynamics, including the trajectory of the effect-site of propofol and systemic exposure. Primary outputs included: plasma and effect-site propofol concentration trajectories; time to peak effect-site concentration; maximum plasma site concentration; duration of infusion; and area under the curve at time-to-peak effect-site concentration. Results were summarised as median (IQR [range]) across bodyweights, with relative differences in proportions reported for time to peak effect-site and plasma concentration.</p><p>Acro
{"title":"Rapid sequence induction with target-controlled infusions: a technical simulation study","authors":"Andrea Gentile, Michele Introna, Michel M. R. F. Struys, Johannes P. van den Berg","doi":"10.1111/anae.70078","DOIUrl":"10.1111/anae.70078","url":null,"abstract":"<p>Target-controlled infusions have been criticised as too slow for a rapid sequence induction (RSI), due primarily to the maximum infusion rate of commercially available pumps (approximately 1200 ml.h<sup>-1</sup>). Despite the widespread adoption of total intravenous anaesthesia, there is limited consensus on what truly defines a ‘rapid’ induction of general anaesthesia, and no standardised description of RSI components exists [<span>1</span>]. A new feature in commercial target-controlled infusion pumps enables administration of an additional manual bolus to accelerate induction of anaesthesia [<span>2</span>]. The rationale relies on comparing a 5 s manual bolus with a capped 1200 ml.h<sup>-1</sup> infusion rate, supported by proof-of-concept simulation in a single virtual subject. This study extends that concept by providing a simulation-based pharmacokinetic proof of feasibility for target-controlled infusions use in RSI.</p><p>Simulations were performed using the Python Anaesthesia Simulator [<span>3</span>], which incorporates the Eleveld population model for propofol. Virtual patients were defined as 35-year-old males, 175 cm in height, with bodyweights ranging from 40 kg to 160 kg and assuming concomitant opioid administration. To isolate the effect of bodyweight on model performance and infusion limitations, we kept age, sex, height and opioid co-administration fixed across simulations, varying weight only. This approach ensured that differences in onset dynamics were attributable to weight-dependent changes in pharmacokinetics and to the infusion-rate cap of the pump, rather than to covariate interactions. Using propofol 1%, three induction doses were evaluated (1.5, 2.0 and 2.5 mg.kg<sup>-1</sup>), administered by two modalities: target-controlled infusion at a high infusion rate of 1200 ml.h<sup>-1</sup>; and a manual bolus delivered at 3360 ml.h<sup>-1</sup>. Without standardised guidelines for propofol administration during RSI, a manual bolus of 2 mg.kg<sup>-1</sup> over 15 s in a 70 kg patient was assumed. Simulation infusions continued until the full dose was delivered.</p><p>Time to peak effect-site concentration was used as a marker of induction speed, while peak plasma concentration of propofol served as a surrogate for risk of overshoot and haemodynamic instability. Although these indices do not capture loss of consciousness directly or clinical responses, they provide mechanistically relevant markers of onset dynamics, including the trajectory of the effect-site of propofol and systemic exposure. Primary outputs included: plasma and effect-site propofol concentration trajectories; time to peak effect-site concentration; maximum plasma site concentration; duration of infusion; and area under the curve at time-to-peak effect-site concentration. Results were summarised as median (IQR [range]) across bodyweights, with relative differences in proportions reported for time to peak effect-site and plasma concentration.</p><p>Acro","PeriodicalId":7742,"journal":{"name":"Anaesthesia","volume":"81 3","pages":"430-433"},"PeriodicalIF":6.9,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/epdf/10.1111/anae.70078","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145516216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nateiya M. Yongolo, Ibrahim G. Simiyu, Stephen A. Spencer, Eve Worrall, Ben Morton, the Multilink Consortium
<p>Multimorbidity, defined as the coexistence of two or more long-term conditions, is a major public health issue. In southern and eastern Africa, limited access to primary care frequently results in delayed diagnosis and chronic disease decompensation with the need for acute hospital admission [<span>1</span>]. This report details 1-year survival and health-related quality of life (HRQoL) data in patients admitted acutely to hospitals in Malawi and Tanzania and follows on from our study that detailed the high prevalence of hypertension (44%); HIV (31%); and diabetes mellitus (27%) in patients admitted to hospital [<span>2</span>].</p><p>We conducted this study in line with our published protocol [<span>3</span>] and with statistical methodology replicated from our multicentre cohort study [<span>2</span>]. Patients were categorised based on the number (none, one and two or more) of long-term conditions. The 1-year follow-up for all patients was completed in December 2024. We evaluated 1-year survival and HRQoL (where a score of 1 represents perfect health and a score of 0 represents death) in survivors using EQ5D-5l. We have provided an open access link to our database hosted at: https://publications.mlw.mw. The 1-year survival analysis for this study was performed in R (4.4.1; R Studio for Statistical Computing, Vienna, Austria) using the survival, survminer and ggplot2 packages and HRQoL analysis was conducted in Stata MP 18.0 (StataCorp, College Station, TX, USA).</p><p>A total of 1407 patients, 657 (47%) female, were recruited to the cohort study between September 2022 and July 2023. One-year outcomes were available for 1244 (88%) patients, with 551 (44%) deaths recorded. There were 161 (11%) patients lost to follow-up at 1 year, and two patients withdrew from the study. There were 416 (54%) deaths at 1 year among those with two or more long-term conditions (Table 1 and online Supporting Information Figure S1). After adjusting for age, sex, universal vital assessment (a context-sensitive early warning score [<span>4</span>]) and site, patients with two or more long-term conditions had a higher risk of mortality compared with those with one long-term condition (hazard ratio 1.89, 95%CI 1.32–2.70) (Fig. 1, online Supporting Information Tables S1 and S2).</p><p>In the unadjusted analysis, the adjusted median (IQR [range]) 1-year HRQoL was lower in patients with two or more long-term conditions compared with those with one long-term condition (0.783 (0.625–1.000 [-0.743–1.000]) vs. 1.000 (0.799–1.000 [-1.069–1.000]), p < 0.001). After adjustment, however, this difference was not statistically significant: coefficient -0.02, 95%CI -0.04 to -0.003, p < 0.095 (online Supporting Information Figure S2 and Table S3).</p><p>We found lower survival for patients with long-term conditions, most commonly HIV, hypertension and diabetes mellitus. This is important because complications from these primary chronic communicable and non-communicable diseas
多重发病是指两种或两种以上长期疾病并存,是一个重大的公共卫生问题。在南部和东部非洲,获得初级保健的机会有限,常常导致诊断延误和慢性疾病失代偿,需要紧急住院。该报告详细介绍了马拉维和坦桑尼亚医院急性住院患者的1年生存率和健康相关生活质量(HRQoL)数据,并遵循了我们的研究,详细介绍了高血压的高患病率(44%);艾滋病毒(31%);住院患者中有糖尿病(27%)。我们按照我们公布的方案[3]和从我们的多中心队列研究[2]复制的统计方法进行了这项研究。患者根据长期疾病的数量(无、一种、两种或更多)进行分类。所有患者的1年随访于2024年12月完成。我们使用EQ5D-5l评估幸存者的1年生存率和HRQoL(1分代表完全健康,0分代表死亡)。我们提供了一个到我们的数据库的开放访问链接:https://publications.mlw.mw。本研究的1年生存分析在R (4.4.1; R Studio for Statistical Computing, Vienna, Austria)中使用survival, survminer和ggplot2软件包进行,HRQoL分析在Stata MP 18.0 (StataCorp, College Station, TX, USA)中进行。在2022年9月至2023年7月期间,共有1407名患者被招募到队列研究中,其中657名(47%)为女性。1244例(88%)患者获得了一年的结果,其中551例(44%)死亡。有161例(11%)患者在1年后失去随访,2例患者退出研究。在患有两种或两种以上长期疾病的患者中,1年内有416例(54%)死亡(表1和在线支持信息图S1)。在调整了年龄、性别、通用生命评估(一个上下文敏感的早期预警评分[4])和地点后,有两种或两种以上长期疾病的患者比只有一种长期疾病的患者有更高的死亡风险(风险比1.89,95%CI 1.32-2.70)(图1,在线支持信息表S1和S2)。在未经调整的分析中,有两种或多种长期疾病的患者1年HRQoL的调整中位数(IQR[范围])低于有一种长期疾病的患者(0.783(0.625-1.000[-0.743-1.000])和1.000 (0.799-1.000 [-1.069-1.000]),p < 0.001)。但调整后,差异无统计学意义:系数-0.02,95%CI -0.04 ~ -0.003, p < 0.095(在线支持信息图S2和表S3)。我们发现长期患病的患者生存率较低,最常见的是艾滋病、高血压和糖尿病患者。这一点很重要,因为如果在继发性并发症发生之前加强卫生系统,这些原发性慢性传染性和非传染性疾病的并发症就有可能得到缓解。例如,我们发现心力衰竭的患病率很高(11%);脑血管意外(9%);慢性肾脏疾病(6%)在我们的队列研究bbb中。如何最好地支持卫生系统和卫生保健工作者提供这些干预措施(例如改进诊断、药物和以患者为中心的护理)是需要解决的一个关键问题。我们建议在已建立的艾滋病毒感染者垂直卫生系统的基础上,为这些环境中的住院患者制定综合护理规划。据我们所知,这是对非洲南部和东部多病住院患者长期预后的首次检查。我们的研究结果与高收入国家的数据形成对比,高收入国家报告的多病bbb患者的死亡率(6%对3%的住院死亡率)和再入院率(1年后39%对25%)更高。我们的HRQoL数据也与先前的研究一致,这些研究报告HRQoL随着入院后90天病情数量的增加而呈剂量依赖性降低[6,7],但在1年的幸存者中未观察到这种影响。在坦桑尼亚和马拉维等资源有限的卫生系统中,应对这一挑战需要双重重点,即为已受影响的人提供适当的护理,同时在初级卫生保健机构中优先考虑初级预防战略,以促进人口健康。在南部和东部非洲,多发病与住院患者预后不良有关,入院1年后死亡率持续上升。未来的研究应确定与当地相关的风险状况,并测试卫生系统层面的干预措施,以更好地控制慢性病,预防急性代偿失调,减轻多病的长期健康后果。
{"title":"One-year follow-up of survival and health-related quality of life in patients with medical conditions admitted acutely to hospital in Malawi and Tanzania","authors":"Nateiya M. Yongolo, Ibrahim G. Simiyu, Stephen A. Spencer, Eve Worrall, Ben Morton, the Multilink Consortium","doi":"10.1111/anae.70083","DOIUrl":"10.1111/anae.70083","url":null,"abstract":"<p>Multimorbidity, defined as the coexistence of two or more long-term conditions, is a major public health issue. In southern and eastern Africa, limited access to primary care frequently results in delayed diagnosis and chronic disease decompensation with the need for acute hospital admission [<span>1</span>]. This report details 1-year survival and health-related quality of life (HRQoL) data in patients admitted acutely to hospitals in Malawi and Tanzania and follows on from our study that detailed the high prevalence of hypertension (44%); HIV (31%); and diabetes mellitus (27%) in patients admitted to hospital [<span>2</span>].</p><p>We conducted this study in line with our published protocol [<span>3</span>] and with statistical methodology replicated from our multicentre cohort study [<span>2</span>]. Patients were categorised based on the number (none, one and two or more) of long-term conditions. The 1-year follow-up for all patients was completed in December 2024. We evaluated 1-year survival and HRQoL (where a score of 1 represents perfect health and a score of 0 represents death) in survivors using EQ5D-5l. We have provided an open access link to our database hosted at: https://publications.mlw.mw. The 1-year survival analysis for this study was performed in R (4.4.1; R Studio for Statistical Computing, Vienna, Austria) using the survival, survminer and ggplot2 packages and HRQoL analysis was conducted in Stata MP 18.0 (StataCorp, College Station, TX, USA).</p><p>A total of 1407 patients, 657 (47%) female, were recruited to the cohort study between September 2022 and July 2023. One-year outcomes were available for 1244 (88%) patients, with 551 (44%) deaths recorded. There were 161 (11%) patients lost to follow-up at 1 year, and two patients withdrew from the study. There were 416 (54%) deaths at 1 year among those with two or more long-term conditions (Table 1 and online Supporting Information Figure S1). After adjusting for age, sex, universal vital assessment (a context-sensitive early warning score [<span>4</span>]) and site, patients with two or more long-term conditions had a higher risk of mortality compared with those with one long-term condition (hazard ratio 1.89, 95%CI 1.32–2.70) (Fig. 1, online Supporting Information Tables S1 and S2).</p><p>In the unadjusted analysis, the adjusted median (IQR [range]) 1-year HRQoL was lower in patients with two or more long-term conditions compared with those with one long-term condition (0.783 (0.625–1.000 [-0.743–1.000]) vs. 1.000 (0.799–1.000 [-1.069–1.000]), p < 0.001). After adjustment, however, this difference was not statistically significant: coefficient -0.02, 95%CI -0.04 to -0.003, p < 0.095 (online Supporting Information Figure S2 and Table S3).</p><p>We found lower survival for patients with long-term conditions, most commonly HIV, hypertension and diabetes mellitus. This is important because complications from these primary chronic communicable and non-communicable diseas","PeriodicalId":7742,"journal":{"name":"Anaesthesia","volume":"81 2","pages":"297-299"},"PeriodicalIF":6.9,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/epdf/10.1111/anae.70083","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145516275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nory Elhadjene, Marlène Damin-Pernik, Serge Molliex, Cédric Delzanno, Louise Triquet
{"title":"Sugammadex hypersensitivity: a national retrospective cohort study from the French pharmacovigilance database","authors":"Nory Elhadjene, Marlène Damin-Pernik, Serge Molliex, Cédric Delzanno, Louise Triquet","doi":"10.1111/anae.70077","DOIUrl":"10.1111/anae.70077","url":null,"abstract":"","PeriodicalId":7742,"journal":{"name":"Anaesthesia","volume":"81 3","pages":"434-435"},"PeriodicalIF":6.9,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/epdf/10.1111/anae.70077","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145515778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Karen Pedersen,Johan van Schalkwyk,Kim Phillips,Henry Wang,Peter Cooke
INTRODUCTIONPeri-operative hypersensitivity reactions are rare and unpredictable events that can result in significant patient harm. Neuromuscular blocking drugs are one of the leading causes of peri-operative hypersensitivity reactions in many parts of the world.METHODSOur retrospective observational cohort study of in adults in New Zealand investigated the incidence and relative risk of a peri-operative hypersensitivity reaction to the various to neuromuscular blocking drugs. We also explored possible cross-sensitivity between the different neuromuscular blocking drugs using skin testing. The incidence of anaphylaxis to neuromuscular blocking drugs was calculated within a subset of our cohort, using confirmed cases of anaphylaxis to each neuromuscular blocking drug as the numerator and number of new patient exposures to the drug as the denominator.RESULTSWe determined the risk of a peri-operative hypersensitivity reaction with individual neuromuscular blocking drugs to be: suxamethonium 1:1500 (95%CI 1000-2500); rocuronium 1:3300 (95%CI 2100-5300); and atracurium 1:15,000 (95%CI 6800-40,000). Female patients were up to eight times more likely to experience a peri-operative hypersensitivity reaction than males. Our skin test results suggest that if a patient experiences a peri-operative hypersensitivity reaction to rocuronium, suxamethonium or vecuronium, then atracurium is the lowest risk alternative. If a patient has had a peri-operative hypersensitivity reaction to atracurium, then rocuronium and suxamethonium are low risk alternatives.DISCUSSIONWe found a significant difference between the rates of peri-operative hypersensitivity reactions with rocuronium and suxamethonium vs. atracurium. The increased risk of a peri-operative hypersensitivity reaction is a factor that should be weighed against the benefits of using suxamethonium or rocuronium. Females may be higher risk than males of reacting to neuromuscular blocking drugs.
{"title":"Peri-operative hypersensitivity reactions to neuromuscular blocking drugs in New Zealand 2013-2019: a retrospective observational study.","authors":"Karen Pedersen,Johan van Schalkwyk,Kim Phillips,Henry Wang,Peter Cooke","doi":"10.1111/anae.70058","DOIUrl":"https://doi.org/10.1111/anae.70058","url":null,"abstract":"INTRODUCTIONPeri-operative hypersensitivity reactions are rare and unpredictable events that can result in significant patient harm. Neuromuscular blocking drugs are one of the leading causes of peri-operative hypersensitivity reactions in many parts of the world.METHODSOur retrospective observational cohort study of in adults in New Zealand investigated the incidence and relative risk of a peri-operative hypersensitivity reaction to the various to neuromuscular blocking drugs. We also explored possible cross-sensitivity between the different neuromuscular blocking drugs using skin testing. The incidence of anaphylaxis to neuromuscular blocking drugs was calculated within a subset of our cohort, using confirmed cases of anaphylaxis to each neuromuscular blocking drug as the numerator and number of new patient exposures to the drug as the denominator.RESULTSWe determined the risk of a peri-operative hypersensitivity reaction with individual neuromuscular blocking drugs to be: suxamethonium 1:1500 (95%CI 1000-2500); rocuronium 1:3300 (95%CI 2100-5300); and atracurium 1:15,000 (95%CI 6800-40,000). Female patients were up to eight times more likely to experience a peri-operative hypersensitivity reaction than males. Our skin test results suggest that if a patient experiences a peri-operative hypersensitivity reaction to rocuronium, suxamethonium or vecuronium, then atracurium is the lowest risk alternative. If a patient has had a peri-operative hypersensitivity reaction to atracurium, then rocuronium and suxamethonium are low risk alternatives.DISCUSSIONWe found a significant difference between the rates of peri-operative hypersensitivity reactions with rocuronium and suxamethonium vs. atracurium. The increased risk of a peri-operative hypersensitivity reaction is a factor that should be weighed against the benefits of using suxamethonium or rocuronium. Females may be higher risk than males of reacting to neuromuscular blocking drugs.","PeriodicalId":7742,"journal":{"name":"Anaesthesia","volume":"29 1","pages":""},"PeriodicalIF":10.7,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145477655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}